People: Targacept, Inc. (TRGT.O)

TRGT.O on Consolidated Issue listed on NASDAQ Global Market

20.51USD
9 Feb 2010
Price Change (% chg)

$0.20 (+0.98%)
Prev Close
$20.51
Open
--
Day's High
$20.86
Day's Low
$20.38
Volume
143,250
Avg. Vol
165,579
52-wk High
$24.50
52-wk Low
$2.00

view people for:

Summary

Name Age Since Current Position
Skaletsky, Mark 61 2002 Chairman of the Board
DeBethizy, J. Donald 58 2000 President, Chief Executive Officer, Director
Musso, Alan 47 2007 Chief Financial Officer, Vice President, Treasurer, Assistant Secretary
Zorn, Peter 38 2007 Vice President - Legal Affairs, General Counsel, Secretary
Bencherif, Merouane 54 2002 Vice President - Preclinical Research
Caldwell, William 55 2002 Vice President - Drug Discovery and Development
Dunbar, Geoffrey 62 2001 Vice President - Clinical Development and Regulatory Affairs
Brennan, Jeffrey 51 2003 Vice President - Business and Commercial Development
Barrett, M. James 66 2002 Director
Blixt, Charles 58 2000 Director
De Souza, Errol 55 2004 Director
Richard, John 51 2002 Director
Burrill, G. Steven 64 2006 Director
Dunton, Alan 55 2006 Director
Snyderman, Ralph 69 2007 Director
Brown, Julia 61 2007 Director
» Insider Trading

Biographies

Name Description
Skaletsky, Mark Mark Skaletsky is Chairman of the Board of Targacept, Inc. He has been a member of the Board since February 2001 and the company's Chairman since January 2002. Since May 2008, Mr. Skaletsky has been the chairman and chief executive officer of Fenway Pharmaceuticals, Inc., a biotechnology company. From March 2001 to March 2008, he served as the chairman and chief executive officer of Trine Pharmaceuticals, Inc., a biotechnology company. From May 1993 to December 2000, he was president and chief executive officer of GelTex Pharmaceuticals, Inc., which was acquired by Genzyme Corporation in December 2000. He is a member of the board of directors of each of the publicly-traded companies Alkermes, Inc., AMAG Pharmaceuticals, Inc. and ImmunoGen, Inc. and a member of the board of trustees of Bentley University.
DeBethizy, J. Donald J. Donald DeBethizy, Ph.D. has been President, Chief Executive Officer, Director of Targacept, Inc. He has been a member of the Board since March 1997. Dr. deBethizy has been the company's Chief Executive Officer since August 2000 and the company's President since March 1997.
Musso, Alan Alan A. Musso has been Chief Financial Officer, Vice President, Treasurer, Assistant Secretary of Targacept, Inc. He has been Vice President, Chief Financial Officer and Treasurer since February 2002 and the company's Assistant Secretary since June 2007. From February 2002 to June 2007, he was the company's Secretary. Mr. Musso is a certified public accountant and a certified management accountant.
Zorn, Peter Peter A. Zorn has been Vice President, Legal Affairs, General Counsel and Secretary of Targacept, Inc. He has been Vice President, Legal Affairs and General Counsel since January 2006 and the company's Secretary since June 2007. From May 2003 to January 2006, he was the company's Corporate Counsel and, from May 2003 to June 2007, he was the company's Assistant Secretary.
Bencherif, Merouane Merouane Bencherif, M.D., Ph.D. has been Vice President, Preclinical Research of Targacept, Inc., since August 2002. From August 2000 to August 2002, he was the company's Vice President, Biological Sciences.
Caldwell, William William S. Caldwell, Ph.D. has been Vice President, Drug Discovery and Development of Targacept, Inc., since August 2002 and has served as chairman of the company's Research and Development Committee since June 2004. From August 2000 to August 2002, he was the company's Vice President, Drug Discovery.
Dunbar, Geoffrey Geoffrey C. Dunbar, M.D. has been Vice President, Clinical Development and Regulatory Affairs of Targacept, Inc., since June 2001.
Brennan, Jeffrey Jeffrey P. Brennan has been Vice President, Business and Commercial Development of Targacept, Inc., since September 2003.
Barrett, M. James M. James Barrett, Ph.D. has been Director of Targacept, Inc., since November 2002. Since September 2001, Dr. Barrett has been a general partner of New Enterprise Associates, a venture capital firm that focuses on the medical and life sciences and information technology industries. He is a member of the board of directors of the publicly-traded company Inhibitex, Inc.
Blixt, Charles Charles A. Blixt has been Director of Targacept, Inc., since August 2000. Since October 2007, Mr. Blixt has been a senior advisor to Jones Day, a law firm. From September 2006 to April 2007, he served as the interim general counsel of Krispy Kreme Doughnuts, Inc., a branded specialty retailer. From August 2004 to August 2006, he was executive vice president, general counsel and assistant secretary of Reynolds American Inc. From June 1999 to August 2006, he held positions of increasing responsibility with R.J. Reynolds Tobacco Holdings, Inc. and, from January 1998 to August 2006, he served as executive vice president and general counsel of R.J. Reynolds Tobacco Company. Mr. Blixt is a member of the board of directors of each of the publicly-traded companies Krispy Kreme Doughnuts, Inc. and Swedish Match AB.
De Souza, Errol Errol B. De Souza, Ph.D. has been Director of Targacept, Inc., since January 2004. Since January 2009, Dr. De Souza has been a pharmaceutical and biotechnology consultant. From April 2003 to January 2009, he served as president and chief executive officer of Archemix Corporation, a privately held biopharmaceutical company. From September 2002 to March 2003, he was president, chief executive officer and a director of Synaptic Pharmaceutical Corporation, a publicly-traded biopharmaceutical company that was acquired by H. Lundbeck A/S in March 2003. Dr. De Souza is a member of the board of directors of each of the publicly-traded companies Bionomics Ltd., IDEXX Laboratories, Inc. and Palatin Technologies, Inc.
Richard, John John P. Richard has been Director of Targacept, Inc., since November 2002. Since June 2005, Mr. Richard has been a managing director of Georgia Venture Partners, LLC, a venture capital firm that focuses on the biotechnology industry. In addition, he has served as senior business advisor to GPC Biotech AG, a drug discovery and development company based in Munich, Germany, since April 1999 and as a consultant to Nomura Phase4 Ventures, a private equity fund, or an affiliated entity since January 2000. Mr. Richard is a member of the board of directors of the publicly-traded company Altus Pharmaceuticals Inc.
Burrill, G. Steven G. Steven Burrill has been Director of Targacept, Inc., since August 2006. Mr. Burrill also previously served as a member of the Board from August 2000 to August 2005. Since January 1997, he has been the chief executive officer of Burrill & Company LLC, a merchant bank that he founded focused on biotechnology, pharmaceuticals, diagnostics, devices, human healthcare and related medical technologies, nutraceuticals and wellness, agricultural biotechnology, and industrial biotechnology. Prior to founding Burrill & Company LLC, Mr. Burrill spent 27 years with Ernst & Young LLP, including the last 17 as a partner of the firm. He is a member of the board of directors of each of the publicly-traded companies DepoMed, Inc. and Pharmasset, Inc.
Dunton, Alan Alan W. Dunton, M.D. has been Director of Targacept, Inc., since October 2006. Since April 2009, Dr. Dunton has been managing director of Panacos Pharmaceuticals Inc., a biotechnology company. From January 2007 to March 2009, he was president and chief executive officer of Panacos Pharmaceuticals. Since January 2006, he has been president of Danerius, LLC, a consultant. From February 2002 to December 2005, he served as chief executive officer of Metaphore Pharmaceuticals, Inc., a biotechnology company. Dr. Dunton is a member of the board of directors of each of the publicly-traded companies MediciNova, Inc. and Panacos Pharmaceuticals Inc.
Snyderman, Ralph Ralph Snyderman, M.D. has been Director of Targacept, Inc., since June 2007. Since July 2004, Dr. Snyderman has been Chancellor Emeritus and James B. Duke Professor of Medicine at Duke University. He is the founder and chairman of Proventys Inc., a developer of diagnostic tools for use with personalized medicine. In addition, he has consulted for New Enterprise Associates as a venture partner since January 2006. From June 1989 to June 2004, Dr. Snyderman served as Chancellor for Health Affairs for the Duke University Health System. From February 1998 to July 2004, he served as president and chief executive officer of the Duke University Health System. Dr. Snyderman is a member of the board of directors of the publicly-traded company The Procter & Gamble Company.
Brown, Julia Julia R. Brown has been Director of Targacept, Inc., since November 2007. From July 2003 to September 2008, Ms. Brown served as an adviser to the chief executive officer of Amylin Pharmaceuticals, Inc., a biopharmaceutical company. From January 2000 until July 2003, she was executive vice president of Amylin Pharmaceuticals, Inc. She is a member of the board of directors of the publicly-traded company Labopharm, Inc.

Options Compensation

Name Options Value
Skaletsky, Mark 0 0
DeBethizy, J. Donald 432,588 54,435
Musso, Alan 148,356 82,500
Zorn, Peter 0 0
Bencherif, Merouane 155,242 0
Caldwell, William 140,426 0
Dunbar, Geoffrey 157,602 75,048
Brennan, Jeffrey 72,533 78,402
Barrett, M. James 0 0
Blixt, Charles 0 0
De Souza, Errol 0 0
Richard, John 0 0
Burrill, G. Steven 0 0
Dunton, Alan 0 0
Snyderman, Ralph 0 0
Brown, Julia 0 0

Insider Trading

Name Shares Traded Price
BENCHERIF MEROUANE 73,108 $20.51
BENCHERIF MEROUANE 19,926 $5.55
BENCHERIF MEROUANE 15,975 $1.75
BENCHERIF MEROUANE 37,207 $5.10
BENCHERIF MEROUANE 7,735 $20.81
ZORN PETER A 4,092 $21.02
ZORN PETER A 4,092 $5.55
ZORN PETER A 312 $21.30
ZORN PETER A 312 $5.10
DUNBAR GEOFFREY C 22,602 $21.86
DEBETHIZY J DONALD 6,769 $3.53
DEBETHIZY J DONALD 28,296 $22.00
BENCHERIF MEROUANE 15,532 $21.93
DEBETHIZY J DONALD 209,004 $21.98
MUSSO ALAN A 1,000 $22.27
BENCHERIF MEROUANE 15,532 $8.51
DEBETHIZY J DONALD 202,235 $1.75
CALDWELL WILLIAM S 23,206 $3.53
MUSSO ALAN A 1,000 $5.10
DEBETHIZY J DONALD 630 $22.99
CALDWELL WILLIAM S 23,206 $21.93
MUSSO ALAN A 11,809 $5.10
BENCHERIF MEROUANE 8,056 $22.19
DEBETHIZY J DONALD 15,391 $22.28
BENCHERIF MEROUANE 8,056 $8.51
» Full list on Insider Trading
view people for: